早期成功的联合抗逆转录病毒治疗可使HIV与HTLV-1合并感染者生存时间正常化
该研究在巴西萨尔瓦多一家艾滋病转诊中心开展嵌套回顾性病例对照研究(1:1),将149例接受cART的HIV/HTLV-1合并感染者按HIV确诊年龄和性别与等量HTLV未感染者匹配。结果显示合并感染者总生存时间短于单感染者,但当HIV病毒载量<50 copies/mL时两组生存时间无差异,提示成功的cART可使合并感染者生存正常化。
要点
- HIV/HTLV-1合并感染者总体生存时间短于HIV单感染者
- HIV病毒载量>50 copies/mL时合并感染者生存时间更短
- 病毒载量<50 copies/mL时合并与单感染者生存时间无差异
核心结论
- 成功的cART(末次HIV病毒载量<50 copies/mL)可使HIV/HTLV-1合并感染者的生存率提高到与HIV单感染者相当的水平。
- 无论CD4细胞计数如何,所有HIV/HTLV-1合并感染者均应启动cART。
研究设计与样本
- 嵌套回顾性病例对照研究(1:1),在巴西萨尔瓦多一家艾滋病转诊中心review医疗记录。
- 149例接受cART的HIV/HTLV-1合并感染者(病例)按HIV确诊年龄和性别与149例HTLV未感染者(对照)匹配。
主要发现
- 总死亡率为2.1人年(76例死亡,其中53例为合并感染者)。
- 合并感染者生存时间为16.7±0.7年,显著短于对照组的18.1±0.4年(P=.001)。
- HIV病毒载量>50 copies/mL者中,合并感染者生存时间8.4±0.8年短于单感染者12.9±1.4年(P=.02),与病毒载量高低无关。
- HIV病毒载量<50 copies/mL者中,单感染者生存时间19.0±0.4年与合并感染者20.2±0.6年无差异(P=.5)。
- 死亡合并感染者初始CD4计数(417±219 cells)高于死亡单感染者(177±160 cells;P=.004),存活者基线CD4计数与HTLV状态无关。
临床怎么用
- 对HIV/HTLV-1合并感染者应尽早启动cART,不以CD4细胞计数作为启动门槛。
- 治疗目标是实现HIV病毒载量持续<50 copies/mL,以缩小合并感染者的生存差距。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Coinfection with human T-cell lymphotrophic virus type 1 (HTLV-1) is associated with shorter survival for adults and children infected with human immunodeficiency virus (HIV), although the reasons remain a matter of debate. We evaluated the factors associated with survival time in a large cohort of HIV/HTLV-1-coinfected and HIV-monoinfected individuals on combination antiretroviral therapy (cART). METHODS: In a nested, retrospective case-control study (1:1), we reviewed medical records of people with HIV infection on cART in a referral AIDS center in Salvador, Brazil. We matched 149 patients coinfected with HTLV-1 (cases) by age at HIV diagnosis and sex, to an equal number of HTLV-uninfected persons (controls). Death rates, survival time, baseline and current CD4 cell count, last HIV-1 RNA plasma viral load (pVL), and causes of death were compared between groups. RESULTS: The overall mortality rate was 2.1 person-years (76 deaths, 53 among coinfected patients). Survival time for cases (16.7 ± 0.7 years) was significantly shorter than for controls (18.1 ± 0.4 years; P = .001). Among patients with pVL >50 copies/mL, coinfected patients had a shorter survival time (8.4 ± 0.8 years) than monoinfected ones (12.9 ± 1.4 years; P = .02), regardless of pVL magnitude. However, survival time did not differ for HIV-monoinfected (19.0 ± 0.4 years) or coinfected patients (20.2 ± 0.6 years) presenting with pVL <50 copies/mL (P = .5). Deceased coinfected patients had higher initial CD4 count (417 ± 219 cells) than monoinfected ones with the same outcome (177 ± 160 cells; P = .004), while survivors had similar CD4 cell count at baseline, regardless of HTLV status. CONCLUSIONS: Successful cART is able to normalize survival for coinfected patients and should be introduced for all coinfected patients, regardless of CD4 cell count.HIV/human T-cell lymphotrophic virus type 1 coinfection is believed to decrease survival of coinfected patients. In this case-control study, we demonstrate that successful combination antiretroviral therapy (last HIV viral load <50 copies/mL) is able to improve survival of coinfected patients to levels observed for those monoinfected.
引用
- Brites C, Miranda F, Luz E, et al. Early and Successful Combination Antiretroviral Therapy Normalizes Survival Time in Patients Coinfected With Human Immunodeficiency Virus and Human T-cell Lymphotrophic Virus Type 1. Clin Infect Dis. 2020. PMID: 31406994. doi:10.1093/cid/ciz756
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。